People with a pathogenic variant in these genes are at a higher risk of developing breast, ovarian or other cancers. Genetic testing for the BRCA1 and BRCA2 pathogenic variants—through a blood sample—can provide further information about your risk for developing breast, ovarian or other cancers.
Who Should Consider BRCA Screening?
According to the National Comprehensive Cancer Network (NCCN) recommendations, BRCA testing is suggested for individuals with a personal or family history of any of the following:
- Early-onset breast cancer (<50 years of age), bilateral breast cancer or triple negative (PR/ER/HER2 negative) breast cancer (<60 years of age)
- Two primary breast cancers or a diagnosis of both breast and ovarian cancer in one individual
- Personal or family history of male breast cancer
- Ovarian cancer at any age
- Ethnicity with a higher mutation frequency (eg. Ashkenazi Jewish)
This BRCA1/2 screening option will detect 10% of the known pathogenic variants related to Hereditary Breast and Ovarian Cancer syndrome. This panel is only to be performed if sequencing of BRCA1/2 has previously been performed and did not reveal any pathogenic variants.
Analytical Sensitivity: ~99%
Clinical Sensitivity: Unknown
Turn around time: Results can be expected 7 business days from the time the sample is received at the laboratory.
Findings are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.
Learn more about why NTD Eurofins has been the laboratory to trust for over 30 years.Learn More
BRCA screening is performed through our sister laboratory, EGL Genetics Eurofins.
EGL Genetics has been providing superior, cutting-edge service for more than 47 years. Their expertise spans common and rare genetic disease testing, genomic variant interpretation, test development, and research. EGL Genetics is a CLIA-certified and CAP-accredited laboratory. They work with clients across the United States and from more than 45 countries to help improve patient diagnosis.